[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-563207-105":53,"doc-detail-563207-en":120},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":113,"head_meta":115,"extra_data":117,"updated_unix":119},105,"en","wegovy-semaglutide-prescribing-information-highlights","WEGOVY (semaglutide) Prescribing Information Highlights","","WEGOVY (semaglutide) is a GLP-1 receptor agonist prescribing information highlight for safe and effective use. It outlines indications for reducing major adverse cardiovascular events and for chronic weight management in adults and eligible pediatric patients, including treatment of noncirrhotic MASH with moderate-to-advanced fibrosis. Contraindications include personal or family history of medullary thyroid carcinoma or MEN 2. Key risks include thyroid C-cell tumors and warnings for pancreatitis, gallbladder disease, hypoglycemia, acute kidney injury from volume depletion, and severe gastrointestinal reactions.",{"@graph":63,"@context":112},[64,80,95],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":41,"@type":70,"position":76},"https://docshare.wps.com/template/letters/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/wegovy-semaglutide-prescribing-information-highlights/563207/",4,{"url":78,"name":59,"@type":81,"author":82,"headline":59,"publisher":85,"fileFormat":88,"inLanguage":57,"description":61,"dateModified":89,"datePublished":89,"encodingFormat":88,"isAccessibleForFree":90,"interactionStatistic":91},"DigitalDocument",{"name":83,"@type":84},"Ben ","Person",{"url":68,"name":86,"@type":87},"DocShare","Organization","application/pdf","2026-10-12",true,{"@type":92,"interactionType":93,"userInteractionCount":4},"InteractionCounter",{"@type":94},"ViewAction",{"@type":96,"mainEntity":97},"FAQPage",[98,104,108],{"name":99,"@type":100,"acceptedAnswer":101},"What is the boxed warning for WEGOVY?","Question",{"text":102,"@type":103},"WEGOVY has a boxed warning about the risk of thyroid C-cell tumors seen in rodents. It is contraindicated in patients with personal or family history of MTC or with MEN 2, and patients should be counseled on potential risk and symptoms.","Answer",{"name":105,"@type":100,"acceptedAnswer":106},"What conditions is WEGOVY indicated to treat?",{"text":107,"@type":103},"WEGOVY is indicated to reduce the risk of major adverse cardiovascular events in adults with established CV disease and obesity or overweight. It is also indicated for excess body weight reduction and long-term weight maintenance, and for noncirrhotic MASH with moderate-to-advanced liver fibrosis in adults.",{"name":109,"@type":100,"acceptedAnswer":110},"How is WEGOVY administered and how does dosing start?",{"text":111,"@type":103},"WEGOVY injection is given once weekly as an adjunct to diet and increased physical activity, injected subcutaneously into the abdomen, thigh, or upper arm, starting at 0.25 mg weekly for 4 weeks with later escalation. WEGOVY tablets are started at 1.5 mg once daily for 30 days, then escalated every 30 days to maintenance dosing.","https://schema.org",{"og:url":78,"og:type":114,"og:title":59,"og:site_name":86,"og:description":61},"article",{"robots":116,"canonical":78},"index,follow",{"doc_id":118,"site_id":56},563207,1791821641,{"code":4,"msg":5,"data":121},{"doc_id":118,"user_id":122,"nickname":83,"user_avatar":123,"doc_module":9,"category_id":40,"category_name":41,"doc_title":59,"doc_description":61,"doc_content":124,"file_id":125,"file_url":126,"file_type":127,"file_size":128,"view_count":4,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":129,"language":130,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":131,"faqs":132,"seo_title":133,"seo_description":61,"update_tm":119,"read_time":35},2336478951081,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","HIGHLIGHTS OF PRESCRIBING INFORMATION  \nThese highlights do not include all the information needed to use WEGOVY® safely and effectively. See full prescribing information for WEGOVY.  \nWEGOVY (semaglutide) injection, for subcutaneous use WEGOVY (semaglutide) tablets, for oral use  \nInitial U.S. Approval: 2017  \nWARNING: RISK OF THYROID C-CELL TUMORS See full prescribing information for complete boxed warning.  \n• In rodents, semaglutide causes thyroid C-cell tumors at clinically relevant exposures. It is unknown whether WEGOVY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined. (5.1, 13.1)  \n• WEGOVY is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors. (4, 5.1)  \n-------------------------RECENT MAJOR CHANGES-----------------------  \nIndications and Usage (1)……………………………….08/2025, 12/2025  \nDosage and Administration (2)…………………………08/2025, 12/2025  \nWarnings and Precautions, Acute Kidney Injury Due to Volume Depletion 5.5)…………..08/2025  \nSevere Gastrointestinal Adverse Reactions (5.6)………………10/2025  \n-------------------------INDICATIONS AND USAGE-------------------------  \nWEGOVY is a glucagon-like peptide-1 (GLP-1) receptor agonist. WEGOVY injection is indicated in combination with a reduced calorie diet and increased physical activity:  \n• To reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. (1)  \n• To reduce excess body weight and maintain weight reduction long term in:  \no Adults and pediatric patients aged 12 years and older with obesity. (1)  \no Adults with overweight in the presence of at least one weightrelated comorbid condition. (1)  \n• For the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in adults. This indication is approved under accelerated approval based on improvement of MASH and fibrosis [see Clinical Studies (14.4)] . Continued approval for this indication may be contingent upon the verification and description of clinical benefit in a confirmatory trial. (1)  \nWEGOVY tablets are indicated in combination with a reduced calorie diet and increased physical activity:  \n• To reduce the risk of major adverse CV events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established CV disease and either obesity or overweight. (1)  \n• To reduce excess body weight and maintain weight reduction long term in adults with obesity, or in adults with overweight in the  \npresence of at least one weight-related comorbid condition. (1) Limitations of Use:  \n• Concomitant use ofWEGOVY (semaglutide) tablets or WEGOVY (semaglutide) injection with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. (1)  \n-----------------------DOSAGE AND ADMINISTRATION------------------  \nIn patients with diabetes, monitor blood glucose prior to starting and during WEGOVY treatment. (2. 1)  \nWEGOVY Injection  \n• Administer WEGOVY injection once weekly as an adjunct to diet and increased physical activity, on the same day each week, at anytime of day, with or without meals. (2. 1)  \n• Inject subcutaneously in the abdomen, thigh, or upper arm. (2. 1)  \n• Initiate at 0.25 mg once weekly for 4 weeks. Then follow the dosage escalation schedule in Table 1, titrating every 4 weeks to achieve the maintenance dosage. (2.2)  \n• The usual recommended maintenance dosage ofWEGOVY injection is 2.4 mg once weekly. Refer to the full PI for maintenance dosages based on th","cbCainJEifR691fA","https://ap.wps.com/l/cbCainJEifR691fA","pdf",1692775,49,"English","# Highlights of Prescribing Information\n## Warning: Risk of Thyroid C-Cell Tumors\n## Recent Major Changes\n## Indications and Usage\n## Dosage and Administration\n## Dosage Forms and Strengths\n## Contraindications\n## Warnings and Precautions","[{\"question\":\"What is the boxed warning for WEGOVY?\",\"answer\":\"WEGOVY has a boxed warning about the risk of thyroid C-cell tumors seen in rodents. It is contraindicated in patients with personal or family history of MTC or with MEN 2, and patients should be counseled on potential risk and symptoms.\"},{\"question\":\"What conditions is WEGOVY indicated to treat?\",\"answer\":\"WEGOVY is indicated to reduce the risk of major adverse cardiovascular events in adults with established CV disease and obesity or overweight. It is also indicated for excess body weight reduction and long-term weight maintenance, and for noncirrhotic MASH with moderate-to-advanced liver fibrosis in adults.\"},{\"question\":\"How is WEGOVY administered and how does dosing start?\",\"answer\":\"WEGOVY injection is given once weekly as an adjunct to diet and increased physical activity, injected subcutaneously into the abdomen, thigh, or upper arm, starting at 0.25 mg weekly for 4 weeks with later escalation. WEGOVY tablets are started at 1.5 mg once daily for 30 days, then escalated every 30 days to maintenance dosing.\"}]","WEGOVY (semaglutide) Prescribing Information Highlights | PDF"]